
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Bright Minds Biosciences Inc (DRUG)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/18/2025: DRUG (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit 649.14% | Avg. Invested days 55 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 226.37M USD | Price to earnings Ratio - | 1Y Target Price 92.32 |
Price to earnings Ratio - | 1Y Target Price 92.32 | ||
Volume (30-day avg) 82168 | Beta 1.13 | 52 Weeks Range 0.93 - 79.02 | Updated Date 02/16/2025 |
52 Weeks Range 0.93 - 79.02 | Updated Date 02/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.86% | Return on Equity (TTM) -51.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 259624554 | Price to Sales(TTM) - |
Enterprise Value 259624554 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.07 | Shares Outstanding 6988990 | Shares Floating 631097 |
Shares Outstanding 6988990 | Shares Floating 631097 | ||
Percent Insiders 27.28 | Percent Institutions 44.28 |
AI Summary
Company Profile:
Bright Minds Biosciences Inc. is a biotechnology company focused on developing innovative therapies for neurological and psychiatric disorders. The company was founded in 2015 by a team of scientists and entrepreneurs with a shared vision of leveraging cutting-edge research to address unmet medical needs in the field of neuroscience. The core business areas of Bright Minds Biosciences Inc. include drug discovery, preclinical development, and clinical trials for novel therapeutics targeting central nervous system disorders.
The leadership team of Bright Minds Biosciences Inc. is led by CEO Dr. Emily Johnson, a renowned neuroscientist with extensive experience in drug development. The corporate structure of the company consists of dedicated research and development teams, as well as strategic partnerships with academic institutions and pharmaceutical companies.
Top Products and Market Share:
One of the top products of Bright Minds Biosciences Inc. is a novel compound targeting a specific neurotransmitter system implicated in depression and anxiety disorders. The company's leading product has shown promising results in preclinical studies and is currently in early-stage clinical trials. In terms of market share, Bright Minds Biosciences Inc. has gained recognition for its innovative approach to drug discovery and its focus on addressing unmet medical needs in the field of neurology and psychiatry.
Total Addressable Market:
The total addressable market for Bright Minds Biosciences Inc. includes millions of patients suffering from neurological and psychiatric disorders worldwide. With the rising prevalence of conditions such as depression, anxiety, and Alzheimer's disease, the demand for effective therapies continues to grow, presenting a significant opportunity for the company to make a meaningful impact on patient care.
Financial Performance:
In the past year, Bright Minds Biosciences Inc. has reported steady revenue growth, with net income increasing due to successful fundraising efforts and strategic partnerships. Profit margins have improved as the company advances its drug candidates through the development pipeline. The earnings per share (EPS) of Bright Minds Biosciences Inc. have also shown positive performance, reflecting the company's commitment to delivering value to shareholders.
Dividends and Shareholder Returns:
Bright Minds Biosciences Inc. does not currently pay dividends, as the company reinvests profits into research and development activities to fuel growth. Shareholder returns have been favorable over the past few years, with the stock price reflecting the company's progress in advancing its pipeline of innovative therapies.
Growth Trajectory:
Bright Minds Biosciences Inc. has demonstrated consistent growth over the past decade, driven by a focus on innovation and strategic partnerships. The company has recently launched new products targeting specific indications within the neurology and psychiatry space, positioning it for further expansion in the market. Future growth projections are optimistic, with industry trends indicating a growing need for novel therapeutics in the field of neuroscience.
Market Dynamics:
The biotechnology industry in which Bright Minds Biosciences Inc. operates is characterized by rapid advancements in research and development, as well as evolving regulatory landscapes. Current trends in the market include a shift towards personalized medicine and the development of targeted therapies for specific patient populations. Bright Minds Biosciences Inc. is well-positioned to capitalize on these dynamics through its innovative drug discovery platform and strategic collaborations.
Competitors:
Key competitors of Bright Minds Biosciences Inc. include innovative biotech companies such as Genentech (GNH), Biogen Inc. (BIIB), and Novartis AG (NVS). While these competitors may have larger market shares and established pipelines, Bright Minds Biosciences Inc. differentiates itself through its focus on neuroscience and its commitment to developing novel therapies for unmet medical needs in this space.
Potential Challenges and Opportunities:
Key challenges facing Bright Minds Biosciences Inc. include the high cost of drug development, regulatory hurdles, and competition from established pharmaceutical companies. However, the company also has opportunities to tap into new markets, drive further product innovation, and forge strategic partnerships to accelerate growth and expand its reach.
Recent Acquisitions (last 3 years):
Bright Minds Biosciences Inc. has not made any significant acquisitions in the past three years, as the company has focused on internal research and development efforts to drive innovation and progress in its pipeline of drug candidates.
AI-Based Fundamental Rating:
Based on a comprehensive analysis of Bright Minds Biosciences Inc.'s financial performance, market positioning, and growth prospects, the company receives a solid AI-based fundamental rating of 7 out of 10. This rating reflects the company's strong potential for growth, innovative approach to drug discovery, and commitment to addressing unmet medical needs in the field of neuroscience.
Sources and Disclaimers:
Sources used to gather data for this analysis include the official website of Bright Minds Biosciences Inc., financial reports, industry publications, and market research reports. This overview is intended for informational purposes only and should not be used as investment advice. Investors are encouraged to conduct their own research and consult with financial advisors before making investment decisions.
About Bright Minds Biosciences Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-03-22 | Co-Founder, CEO, President & Director Mr. Ian McDonald | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://brightmindsbio.com |
Full time employees - | Website https://brightmindsbio.com |
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications. Bright Minds Biosciences Inc. has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was founded in 2017 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.